New ASCP Review Examines Antidepressant Discontinuation Symptoms Amid Growing Scientific and Public Debate

BRENTWOOD, TN, UNITED STATES, August 10, 2026 /EINPresswire.com/ — A newly published review by members of the American Society of Clinical Psychopharmacology (ASCP) examines what current evidence shows and does not show about symptoms following antidepressant discontinuation, offering clinicians a framework for distinguishing acute discontinuation symptoms from delayed or persistent symptoms.

The authors emphasize an important distinction: acute antidepressant discontinuation symptoms are real and well established, but the scientific picture becomes considerably less certain when symptoms first emerge long after a medication has been eliminated from the body or persist for unusually long periods.

What the Evidence Shows
Meta-analyses cited in the review estimate a placebo-subtracted incidence of approximately 8% to 28% for physical discontinuation symptoms among people with major depressive disorder or anxiety disorders who abruptly stop a short half-life SSRI or SNRI after more than one month of treatment. Typical symptoms include dizziness, nausea, vertigo, nervousness, insomnia, imbalance, sensory disturbances such as “brain zaps,” and hyperarousal. They generally resolve within one to two weeks and are routinely managed via slow dosage tapers over several weeks.

An Unsettled Picture for Delayed or Protracted Symptoms
The review also examines reports of protracted or delayed symptoms, including what has sometimes been called “post-acute withdrawal syndrome” or PAWS. The evidence is substantially less definitive: The authors report that they found no established physiological mechanism adequately explaining pharmacodynamically mediated symptoms that newly arise long after an antidepressant has been stopped.

Clinical Implications
The authors conclude that acute antidepressant discontinuation symptoms occur in about one-third or fewer of people who stop taking an SSRI or SNRI and are generally short-lived and self-limited. The discontinuation of an antidepressant should be individualized to each patient, some individuals requiring a slower-than-typical dose taper.

Clinical depression is a medical condition that often recurs and sometimes requires indefinite or lifelong treatment. Clinicians should therefore carefully evaluate patients’ physical or emotional symptoms after stopping an antidepressant to differentiate drug discontinuation effects from signs of a relapsing, untreated, underlying mental health condition. Misattribution of physical symptoms following antidepressant cessation to antidepressant withdrawal effects rather than other equally plausible causes (e.g., recurrence, psychological distress, expectancy bias) may create problematic anti-medicine bias, driving those who most need it away from lifesaving medical interventions.

Call to Action
The American Society of Clinical Psychopharmacology hopes that advancing research on who, when, and how to prescribe and deprescribe antidepressants encourages a focus on improving patients’ quality of life. With our publication, we hope to highlight both what is known and not known about antidepressant cessation, encouraging both further research and informed patient care.

Article Citation
Goldberg JF, Crismon ML, Goodman DW, et al. When do physical symptoms after antidepressant cessation reflect pharmacodynamic versus non-pharmacodynamic clinical phenomena? J Clin Psychiatry. 2026;87(4):26ac16648. Published online August 6, 2026. https://www.psychiatrist.com/jcp/physical-symptoms-antidepressant-cessation-pharmacodynamic-vs-nonpharmacodynamic-phenomena/

About the American Society of Clinical Psychopharmacology (ASCP)
ASCP is a professional organization dedicated to advancing the science, practice, and education of clinical psychopharmacology to improve the health and well-being of patients. ASCP serves a diverse membership of psychiatrists, researchers, and other mental health professionals across the USA and internationally, providing access to cutting-edge research, educational opportunities, and networking with leaders in psychiatric treatment. The organization publishes through its official journal, The Journal of Clinical Psychiatry, and hosts an annual scientific meeting for professionals in the field. For more information, visit ascpp.org.

Rachel DeAngelo
American Society of Clinical Psychopharmacology
+1 615-649-3088
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X

Media gallery

About The Author

Written By: EIN Presswire